PHS
NBIX icon

PFM Health Sciences’s Neurocrine Biosciences NBIX Stock Holding History

PFM Health Sciences’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-261,500
Closed -$25.1M – 84
2021
Q3 		$25.1M Buy
+261,500
New +$24.7M 0.74% 46

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PFM Health Sciences's NBIX Position: Q1 2026 in Review

PFM Health Sciences increased its Neurocrine Biosciences (NBIX) stake by 32% in Q1 2026, buying an estimated $6.96M and bringing the position to 215,678 shares worth $28.4M. The position accounts for 2.59% of the portfolio, ranked #9.

PFM Health Sciences first reported a position in NBIX in Q1 2021 and has held it in 9 quarters since. The position peaked at $109M in Q2 2021. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • PFM Health Sciences held 215,678 shares of Neurocrine Biosciences worth $28.4M as of Q1 2026.
  • PFM Health Sciences bought 52,481 Neurocrine Biosciences shares in Q1 2026, an estimated $6.96M.
  • Neurocrine Biosciences made up 2.59% of PFM Health Sciences's portfolio in Q1 2026, its #9 holding.
  • PFM Health Sciences first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 9 quarters since.
  • PFM Health Sciences's Neurocrine Biosciences position peaked at $109M in Q2 2021.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.